Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.014 SGD
−10.79 M SGD
5.96 M SGD
453.66 M
About IX BIOPHARMA
Sector
CEO
Yip Hang Lee
Headquarters
Singapore
Website
Founded
2004
ISIN
SG1BD9000009
FIGI
BBG009LDQGX8
iX Biopharma Ltd. engages in the provision of development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. It operates through the Specialty Pharmaceutical and Nutraceutical segments. The Specialty Pharmaceutical segment develops, manufactures and sells pharmaceutical and nutraceutical products. The Nutraceutical segment offers nutraceutical products. The company was founded by Yip Hang Lee on May 8, 2004, and is headquartered in Singapore.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 42C is 0.023 SGD — it hasn't changed in the past 24 hours. Watch IX BIOPHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SGX exchange IX BIOPHARMA stocks are traded under the ticker 42C.
42C stock hasn't changed in a week, the month change is a −8.00% fall, over the last year IX BIOPHARMA has showed a −50.51% decrease.
42C stock is 4.55% volatile and has beta coefficient of 0.70. Track IX BIOPHARMA stock price on the chart and check out the list of the most volatile stocks — is IX BIOPHARMA there?
Yes, you can track IX BIOPHARMA financials in yearly and quarterly reports right on TradingView.
IX BIOPHARMA is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
42C net income for the last half-year is −3.46 M SGD, while the previous report showed −7.33 M SGD of net income which accounts for 52.72% change. Track more IX BIOPHARMA financial stats to get the full picture.
No, 42C doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 59.00 employees. See our rating of the largest employees — is IX BIOPHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IX BIOPHARMA EBITDA is −6.93 M SGD, and current EBITDA margin is −111.21%. See more stats in IX BIOPHARMA financial statements.
Like other stocks, 42C shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IX BIOPHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IX BIOPHARMA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IX BIOPHARMA stock shows the sell signal. See more of IX BIOPHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.